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Abstract 
 
  This present work describes an effective new method for study traditional Chinese medicine (TCM) on meridian 
tropism (MT) theory, which plays an essential role in clinical selection of TCM according to syndromes and strengthens the 
therapeutic effects. The new thread included material basis foundation and its tissue distribution study. Xiheliu, the most 
popular TCM on heart tropism, was investigated by simple and accurate high performance liquid chromatography (HPLC) 
method. The analysis of plasma after oral administration the total flavonoid of Xiheliu (TFX) exhibited that tamarixetin and 
kaempferide had the highest concentration and approximately the highest level within 25 min. The mixture of them could last 
accelerating the urine excretion more than 7 h after a single dose and could not cause the disorder of ion in rats, which was 
observed in diuretic activity experiment. In view of the reported biological activities was consistent with the effects of 
Xiheliu, tamarixetin and kaempferide were likely to be the material basis of it. Tissue distribution study showed that the 
highest level of analytes was in heart, lung, kidney and liver, and most tissues reached maximum level at 30 min post-dose. 
Since liver was the most important blood-supply tissue, the result of this experiment was in accordance with the MT record of 
Xiheliu and confirmed that tamarixetin and kaempferide was the material bases of it on MT. This is the first report for the 
illumination of material basis and the mechanism of Xiheliu on MT by analysis the record of Xiheliu in Compendium of 
Materia Medica and experimental study. 
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Introduction 
 
     MT theory, the core principle of TCM theory and the bridge between TCM theory and clinical medication (Huang and 
Tang, 2009), was found initially in “Huang Di Nei Jing”, which was the origin of TCM theory. After development of MT 
theory in Ming dynasty (1368-1644), especially included in Compendium of Materia Medica (Chinese name: Ben Cao Gang 
Mu), MT theory played an essential role in clinical selection of TCM according to syndromes and the therapeutic effects 
improvement (Zhao et al., 2008), and became the most important part of herbal description and clinical principles in China. 
The study of MT theory contributed to the efficient utilization and modernization of TCM. 
     Xiheliu, the twig of Tamarix chinensis, was the most popular TCM on heart tropism. Described in Compendium of 
Materia Medica, it had diuretic effect, could treat alcoholic damage and abdominal distension caused by parasite or dyspepsia. 
It was also used for the treatment of cough with dyspnea, wind chill cold, rheumatic bone pain and pruritus in China (Chinese 
pharmacopeia committee, 2010). The pharmacological study revealed Xiheliu extract owning good antihepatotoxic activity 
(Yang et al., 1987). It also could kill Pneumococcus, alpha-Streptococcus, Monilia albican, Haemophilus influenzae in vitro 
(Jiang and Zuo, 1988), and inhibit the growth of kinds of pest’s larvae (Klocke et al., 1986). Clinical tests indicated the 
extract not only was good for treating rheumatoid arthritis (Wu, 1996), but also had significant analgesia and antipyretic 
effects (Zhao, 1995).  
     The variation of the cyclic adenosine monophosphate and the cyclic guanosine monophosphate, receptor theory and 
carrier theory had been used for MT theory explaination in the past (Zhao and Wei, 2003). At present, observation of the 
active compound and microelements distribution in vivo was the most popular experimental method for studying MT theory 
(Zhao et al., 2002; Xu, 2004). Every TCM had more than one active compound and variety of biological activities, how to 
find some certain active compound which owns the effects of TCM and do researches in further is the critical and complex 
problem.  
     Material basis was some constituents that possess the main effects of whole herbal. Therefore, finding material basis of 
TCM on MT was regarded as the most important thing to clarify the mechanism and the selectivity of drug actions in essence 
(Zhou, 2009). This paper was designed to determine the material basis of Xiheliu on MT theory, the plasma analysis and 
diuretic activity after oral administration were studied. After a single dose, the distribution of material basis in vivo was 
investigated and found tissue distribution result was consistent with the description of Xiheliu on MT in Compendium of 
Materia Medica. This result indicated that distribution of material basis was useful to clarify the mechanism of Xiheliu on 
MT. As we know, no literature was found on the study of TCM on MT through the material basis and its tissue distribution, 
and this is the first investigation on experimental study of Xiheliu on MT after oral administration the total flavonoid of 
Xiheliu (TFX) in rats.  
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Materials and Methods 
 
Plant Source and Extract 
 
     Xiheliu was purchased from Tongrentang Drugstore (Lianyungang, Jiangsu Provincem, P. R. China). A voucher 
specimen (No. HS100305) was deposited in the Jiangsu Key Laboratory of Marine Biotechnology, Huaihai Institute of 
Technology. Xiheliu (3 kg) was extracted with 75% ethanol aqueous (3 × 1.5 h) under reflux. After evaporation of ethanol in 
vacuo, the concentrated extract was suspended in water and got supernatant by centrifugation, then the supernatant subjected 
to polyamide column and eluted by ethanol aqueous gradient solution. The total flavonoid of Xiheliu (TFX) was obtained 
from the 60% ethanol aqueous eluted fraction.  
 
Chemicals and Drugs 
 
     Tamarixetin and kaempferide were isolated from TFX, their structures were identified on the basis of spectral data 
(Galeotti et al., 2008; Blasa, 2011) and the purity was more than 98.5%. Quercetin used as internal standard (IS) and its purity 
was more than 99.0%. HPLC-grade methanol was purchased from Honeywell International (Burdick and Jackson, Muskegon, 
MI, USA). Pure tamarixetin and kaempferide solutions were prepared in methanol to furnish working solutions at 
concentrations 800, 400, 160, 80, 16.0, 8.00, 3.20, 1.60 μg/mL and 1400, 700, 280, 140, 28.0, 14.0, 5.60, 2.80 μg/mL, 
respectively. Quercetin solution of concentration 275 μg/mL was prepared in methanol. For tissue distribution study, above 
working solutions were diluted by methanol and obtained the standard calibration sample in the concentration range of 
0.32-160 μg/mL, 0.28-280 μg/mL and 27.5 μg/mL, respectively. All the solutions were stored at -20 ºC and were brought to 
room temperature before use.  
     The TFX was distributed in 0.5% sodium carboxymethyl cellulose solution and the finial concentration was 30 mg/mL. 
Each rat was dosed 600 mg/kg of TFX solution orally, which contained 127 mg/kg tamarixetin and 103 mg/kg kaempferide, 
respectively.  
 
Experimental Animals 
 
     Wistar rats (male, 150-170 g) were purchased from Lianyungang Institute of Drug Control (Lianyungang, P. R. China), 
and kept in environmentally controlled breeding room (relative humidity: 65%, temperature: 23 ± 2 ºC, 12 h light-12 h dark 
cycle) for three days before the test, fed with food and water ad arbitrium. All animal studies were performed according to 
the requirement of the National Act on the Use of Experimental Animal (China). The experimental protocol was approved by 
the Committee on Animal Research, Lianyungang City. 
 
HPLC System and Mobile Phase   
 
     Chromatographic analysis was performed on Waters 2695 HPLC system equipped with diode array detector (2996) and 
Empower software (Waters, Milford, MA, USA). A Waters SunfireTM C18 reversed-phase column (5-μm particles, 250 mm × 
4.6 mm) was used for separation and quantification. Chromatograms were monitored at 254 nm and the temperature of 
column was kept at 35 ºC. C18 cartridge columns, purchased from Waters (Waters, Milford, MA, USA), were used for 
samples preparation. The mobile phase for HPLC analysis consisted of methanol (component A) and 0.15% formic acid 
solution (component B, pH 2.7) with a flow rate of 1.0 mL/min, and the change of gradient was different for plasma and 
tissue samples. For plasma samples, the initial elution condition was 10:90 (A-B, v/v) and held for 5 min, linearly changed to 
20:80 (A-B, v/v) at 10 min, to 30:70 (A-B, v/v) at 15 min, to 55:45 (A-B, v/v) at 23 min, to 65:45 (A-B, v/v) at 30 min, and 
to 70:30 (A-B, v/v) at 35 min, successively, then held 70:30 (A-B, v/v) until 40 min. For tissue samples, the initial mobile 
phase composition condition was A-B 10:90 (v/v). This was changed linearly to A-B 35:65 (v/v) at 15 min and held at this 
composition until 25 min, the composition was changed linearly to A-B 60:40 (v/v) at 40 min.  
 
Plasma Analysis Experiment 
 
     18 rats were used for plasma samples collection and ten rats were free of TFX to collect blank plasma. Blood was 
collected from the retrobulbar capillary plexus at 5, 10, 15, 20, 25, 30, 40, 60, 120, 180 and 240 min after oral administration. 
Blank samples were collected at the same time points, and five duplicates were obtained at every time interval. Plasma was 
separated from blood samples by centrifugation at 3500 rpm (10 min), and stored at -20 ºC until analysis. A 200 μL plasma 
sample was removed to a 1.5 mL eppendorf tube and spiked with 5 μL of IS, with adjusting pH to 3.0 using 20 μL 1% 
phosphoric acid solution. The mixed solution was vortexed about 60 seconds and removed to SPE cartridge, which was 
eluted by water (0.4 mL) and methanol (0.4 mL) successively. The methanol fraction was evaporated to dryness under a 
stream of nitrogen at 40 ºC. The residue was reconstituted in 200 μL of methanol and stored at 4 ºC for 30 min, then 
centrifuged (12000 rpm) for 10 minand and 20 μL of the sample was injected into HPLC system for analysis. 
 
Diuretic Activity Study 
 
     50 rats were divided into five groups randomly, two groups of animal were taken as blank control group (water) and 
positive control group (furosemide), and three groups were oral administration the mixture of tamarixetin and kaempferide 
(weight ratio consistent with the proportion of TFX) at three different doses. Before the experiment, all rats were dosed 40 
mL/kg normal saline solution orally, 20 min later, five groups of animal were administrated 2.3, 4.6 and 9.2 mg/kg mixture, 
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10 mL/kg water, 2.0 mg/kg furosemide, respectively. The urine samples were collected during the following time range 0-1, 
1-3, 3-5, 5-7, 7-9, 9-11, 11-15 and 15-24 h after oral administration, and the actual volume of each urine sample was recorded. 
The urine of each group had been mixed in one test tube for ion analysis and pH study. 
 
Tissue Distribution Study  
     Tissues of 20 rats were removed at 10, 30, 60 and 90 min after dosing TFX, washed with physiological saline solution 
and blotted dry twice, finally weighed and stored at -20ºC until disposal (within 24 h). Blank tissues were collected from rats 
free of TFX and processed as tissue samples. 0.5 g tissues (heart, liver, spleen, lung, kidney and brain) were shredded in 
ice-bath, and then homogenized in 4 mL ice-cold 1% phosphoric acid normal saline solution. The homogenate was added 10 
μL IS and vortex-mixed for 60 seconds. The supernatant, prepared by centrifugation at 6000 rpm (10 min), was extracted by 
C18 cartridge and eluted with water (0.6 mL) and methanol (0.6 mL) successively. The methanol fraction was evaporated to 
dryness under a stream of nitrogen at 40 ºC. The residue was redissolved in 100 μL of methanol, and then stored 30 min at 4 
ºC. A 10 μL aliquot was injected into HPLC system after centrifugation at 12000 rpm for 10 min. 
 
HPLC Method Validation 
 
     Calibration curves were constructed by plotting peak area versus concentrations in the standard samples. The limit of 
detection (LOD) and limit of quantitation (LOQ) were determined to evaluate the sensitivity, defined as the concentration that 
produced a signal-to-noise ratio of 3:1 and 10:1, respectively. Intra- and inter-day precision, assessed by relative standard 
deviation (RSD) and mean concentration, were measured by performing replicate analysis (n = 5) for each concentration 
within one day and three continual days. The recoveries from biological samples were calculated by comparing peak areas 
extracted from biological samples with those of the same quantities added to the mobile phase. The freeze-thaw stability was 
tested after frozen at -20 ºC for 24 h and completely thawed at room temperature. The long-time stability and short-time 
stability was assessed within the 30 days (-20 ºC) and 24 h storage periods (room temperature). All samples were tested at 
three concentration levels and repeated at least three times in method validation section.  
 
 
 
 
Results  
Method Validation  
 
     Extract recovery, selectivity, sensitivity, stability, precision and accuracy studies were carried out for HPLC method 
validation. The extraction recoveries of tamarixetin, kaempferide and IS in plasma and tissues were more than 86.4% (Table 
1 and 2), which guaranteed that the measured concentration approach the real one. After removing interferences from the  
 
 
Table 1: Intra- and inter-day accuracy and precision and recovery for kaempferide and tamarixetin in rat plasma 
Intra-day (n = 5) Inter-day (n = 5) Spiked 
concentration 
(μg/mL) Measured concentration  RSD (%) 
(μg/mL) 
 
Measured concentration   RSD (%) 
(μg/mL) 
Recovery 
(%) 
(n = 5) 
RSD 
(%) 
kaempferide 
700 
140 
14 
 
 
706 ± 9.48         1.34 
134 ± 6.86         5.11 
12.9 ± 0.87         6.75 
  
  698 ± 14.3           2.05 
  134 ± 7.48           5.60 
  12.2 ± 1.06           8.69 
 
100 ± 1.27 
95.4 ± 2.19 
89.6 ± 6.74 
 
 
1.25 
2.30 
7.52 
 
tamarixetin 
800 
160 
16 
 
quercetin 
1100 
275 
11 
 
801 ± 15.6         1.95 
162 ± 10.6         6.56 
15.6 ± 0.947        6.07 
 
 
 
 
 
  
  785 ± 19.5           2.48 
 157 ± 7.14           4.56 
  15.1 ± 0.831          5.51 
 
 
 
 
 
 
99.5 ± 2.61 
98.4 ± 4.06 
96.2 ± 6.25 
 
 
98.7 ± 1.36 
98.3 ± 1.79 
97.6 ± 2.94 
 
2.62 
4.13 
6.50 
 
 
1.38 
1.82 
3.01 
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Table 2: Recovery for kaempferide, tamarixetin and quercetin in rat tissues (n = 5) 
Spiked concentration (μg/mL) 
quercetin tamarixetin kaempferide 
 
Tissues 
Recovery (%) 
and RSD 
275 800 160 16 700 140 14 
Recovery 87.7 ± 1.97 93.7±1.61 88.6±2.35 89.1±1.24 93.5±2.13 89.3±1.87 89.5±2.57 Heart 
RSD 2.24 1.72 2.65 1.39 2.28 2.09 2.87 
Recovery 89.7 ± 3.15 92.6±0.94 91.5±2.84 88.2±2.06 90.6±1.48 90.5±2.39 88.9±3.47 Liver 
RSD 3.52 1.02 3.10 2.34 1.63 2.64 3.90 
Recovery 90.6 ± 2.68 92.2±2.18 91.1±1.26 90.8±3.28 91.5±3.24 91.8±2.24 87.4±2.26 Spleen 
RSD 2.95 2.36 1.38 3.61 3.54 2.44 2.59 
Recovery 88.4 ± 2.84 87.6±2.54 86.5±2.96 86.4±1.42 87.2±2.73 87.5±2.83 87.1±2.36 Lung 
RSD 3.29 2.93 3.46 1.65 3.13 3.23 2.71 
Recovery 88.1 ± 3.54 91.8±2.18 89.6±3.58 86.6±2.85 87.5±2.64 88.7±2.34 87.6±3.52 Kidney 
RSD 4.01 2.37 4.00 3.29 3.13 2.98 4.02 
Recovery 88.2±2.97 89.6±3.15 87.8±2.43 87.7±3.57 88.6±2.31 87.6±3.61 87.8±2.16 Brain 
RSD 3.38 3.52 2.77 4.07 2.61 4.12 2.46 
 
 
 
 
 
 
 
 
 
Table 3: Intra- and inter-day accuracy and precision in tissues (n = 5) 
Measured concentration (μg/mL) and RSD (%) Comp- 
ounds 
Spiked 
concentration 
(μg/mL) 
Intra-/inter-day 
Heart Liver Spleen Lung Kindey Brain 
784±20.2 792±19.6 804±23.3 765±18.3 773±26.2 796±23.1 Intra-day 2.58 2.48 2.90 2.39 3.39 2.90 
778±25.4 783±21.5 791±16.8 785±20.3 762±22.8 779±21.7 800 Inter-day 3.26 2.75 2.12 2.59 2.99 2.79 
146±6.44 152±10.5 158±7.64 137±5.38 144±6.21 154±9.83 Intra-day 4.41 6.91 4.84 3.93 4.31 6.38 
151±7.56 141±12.8 150±6.89 144±6.47 143±5.71 161±8.90 160 Inter-day 5.01 8.89 4.59 4.49 3.99 5.53 
13.4±1.03 14.2±0.940 15.2±1.33 12.8±0.87 13.6±1.21 14.6±0.977 Intra-day 7.69 6.62 8.75 6.80 8.90 6.69 
14.9±0.972 13.8±1.09 14.5±1.12 13.1±1.04 14.2±1.32 13.9±1.25 
Tama- 
rixetin 
16 
Inter-day 6.52 7.90 7.72 7.94 9.30 8.99 
675±17.5 683±20.0 699±24.1 674±21.4 679±18.2 688±21.2 Intra-day 2.59 2.93 3.45 3.18 2.68 3.08 
688±14.6 684±21.5 674±20.8 661±22.3 676±17.4 678±22.5 700 Inter-day 2.12 3.14 3.09 3.37 2.57 3.32 
123±5.60 134±8.66 136±6.75 128±6.84 127±7.05 136±8.95 Intra-day 4.55 6.46 4.96 5.34 5.55 6.58 
127±6.99 131±7.00 140±10.8 122±9.32 124±6.38 128±10.1 140 Inter-day 5.50 5.34 7.71 7.64 5.15 7.89 
11.1±0.785 12.8±1.07 13.4±1.19 11.2±0.704 12.5±1.07 13.2±1.10 Intra-day 7.07 8.36 8.88 6.29 8.56 8.33 
11.6±1.13 12.2±1.05 12.9±0.912 11.4±0.883 11.6±0.983 12.7±0.894 
Kaem- 
pferide 
14 
Inter-day 9.74 8.61 7.07 7.75 8.47 7.04 
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Table 4: Calibration curves for kaempferide and tamarixetin in plasma and tissues. (Y, peak area ratio (analyte/IS); X, 
concentration of the tamarixetin and kaempferide (μg/mL); LOQ, S/N = 10:1; LOD, S/N = 3:1.) 
Compounds Standard curves r Test range  
(μg/mL) 
LOD  
(μg/mL) 
LOQ 
 (μg/mL) 
kaempferide (in plasma) 
tamarixetin (in plasma) 
Y=0.00276X - 0.0448 
Y=0.00269X - 0.0219 
0.999 
0.998 
14-1400 
16-800 
0.12 
0.08 
0.24 
0.16 
kaempferide（in heart） Y=0. 00336X+0.0411 0.994 0.28-280  0.10 0.20 
tamarixetin（in heart） Y=0. 00352X+0.0341 0.993 0.32-160 0.06 0.16 
kaempferide (in liver) Y=0. 00343X+0.0423 0.996 0.28-280 0.10 0.20 
tamarixetin (in liver) Y=0. 00347X+0.0402 0.996 0.32-160 0.06 0.16 
kaempferide (in spleen) Y=0. 00341X+0.0435 0.995 0.28-280 0.10 0.24 
tamarixetin (in spleen) Y=0. 00354X+0.0369 0.996 0.32-160 0.06 0.20 
kaempferide (in lung) Y=0. 00332X+0.0431 0.993 0.28-280 0.10 0.20 
tamarixetin (in lung) Y=0. 00338X+0.0472 0.991 0.32-160 0.06 0.16 
kaempferide (in kidney) Y=0. 00329X+0.0443 0.994 0.28-280 0.10 0.20 
tamarixetin (in kidney) Y=0. 00342X+0.0360 0.995 0.32-160 0.06 0.20 
kaempferide (in brain) Y=0. 00343X+0.0414 0.995 0.28-280 0.10 0.24 
tamarixetin (in brain) Y=0. 00337X+0.0318 0.993 0.32-160 0.06 0.16 
 (Y, peak area ratio (analyte/IS); X, concentration of the tamarixetin and kaempferide (μg/mL); LOQ, S/N = 10:1; LOD, S/N 
= 3:1.) 
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Table 5: Stability data for the tamarixetin and kaempferide in rat plasma (n = 3) 
 
Measured concentration  (μg/mL) 
Short-time Long-time Freeze-thaw 
Comp- 
ounds 
Spiked 
concentration 
(μg/mL) 4 hours 12 hours 24 hours 1 day 6 days 30 days 1 cycle 2 cycles 3 cycles 
800 791±10.3 770±14.7 742±17.3 792±17.5 781±19.6 777±18.6 796±14.8 778±16.8 758±15.6 
160 155±5.06 151±4.37 146±5.65 154±1.15 153±3.90 151±4.35 153±4.53 149±3.65 147±6.16 Tamar- ixetin 
16 14.7±0.700 14.4±0.787 14.0±0.668 15.1±0.634 15.0±1.22 14.7±0.534 14.9±0.708 14.6±0.845 14.1±0.827 
700 681±12.7 677±14.8 645±15.3 694±11.4 685±9.88 674±12.4 693±178 671±11.5 663±17.2 
140 132±2.98 133±4.35 127±6.55 133±7.24 130±6.34 126±8.08 129±8.97 126±7.60 123±6.01 Kaem- pferide 14 12.8±0.614 12.6±0.914 12.2±0.848 12.8±1.02 12.4±0.959 12.2±0.852 12.5±0.584 12.1±0.898 12.1±1.08 
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Figure 1: Chromatographic profiles of tissue and plasma samples: blank heart (A); blank heart spiked with tamarixetin, kaempferide and quercetin (B); heart obtain at 30 min after administration 
(C); blank plasma (D); blank plasma spiked with tamarixetin, kaempferide and quercetin (E); plasma sample obtain at 30 min after administration (F). 
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Table 6: Stability data for the tamarixetin and kaempferide in rat tissues (n = 3) 
Measured concentration  (μg/mL) Compounds 
Spiked 
concentration 
(μg/mL) 
Time 
piont 
Heart Liver Spleen Lung Kindey Brain 
3 
cycles 734±18.9 746±24.7 722±25.2 714±17.6 738±19.7 724±17.0 
30 
days 750±18.8 741±21.5 738±24.7 693±20.3 734±19.2 717±26.1 
800 
24 h 730±24.7 726±21.4 714±31.7 660±42.6 705±27.7 682±18.9 
3 
cycles 147±6.11 132±7.76 142±8.45 143±6.53 147±5.56 142±5.37 
30 
days 142±7.60 146±5.44 146±7.16 137±5.73 143±6.82 140±6.88 
160 
24 h 137±5.90 140±7.71 140±7.82 141±6.05 146±10.7 138±6.95 
3 
cycles 14.4±0.678 14.0±0.616 14.4±0.442 13.9±0.671 14.4±0.879 13.9±0.901 
30 
days 14.3±0.547 14.1±0.896 14.5±0.685 13.8±0.647 14.0±0.666 14.2±0.760 
Tamarixetin 
16 
24 h 13.8±0.725 13.7±0.582 13.9±0.751 14.1±0.733 13.7±0.607 13.9±0.972 
3 
cycles 650±13.2 638±21.6 627±22.9 624±23.4 639±24.1 625±24.6 
30 
days 654±21.8 634±17.4 640±23.0 615±26.0 648±24.4 622±23.2 
700 
24 h 639±24.3 622±31.9 666±32.7 612±27.0 627±26.7 600±34.0 
3 
cycles 126±4.75 125±5.10 129±4.61 124±6.26 125±5.03 125±5.82 
30 
days 125±5.42 127±4.75 128±5.94 123±5.36 124±5.96 123±7.08 
140 
24 h 123±.61 122±8.32 124±7.95 121±7.55 121±6.56 121±6.29 
3 
cycles 12.4±0.598 12.4±0.609 12.3±0.768 12.5±0.784 12.2±0.889 12.1±0.820 
30 
days 12.5±0.715 12.5±0.792 12.3±0.736 12.3±0.997 12.3±0.776 12.3±0.738 
Kaempferide 
14 
24 h 12.1±0.822 12.0±0.885 12.2±1.02 12.0±0.942 12.2±0.836 12.0±0.931 
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biological samples by solid-phase extraction, the endogenous components were disappeared at the retention time of  
analytes in plasma and tissues analysis (Figure1). The well-defined analyte peaks demonstrated that acceptable selectivity 
was obtained by using this method. The measured mean concentration was very close to the added concentration (plasma 
samples: >87.1%, tissue samples: >79.3%), the RSD of analytes were less than 8.90% (intra-day, plasma samples: <6.75%, 
tissue samples: <8.90%) and 9.74% (inter-day, plasma samples: <8.69%, tissue samples: <9.74%), respectively (Table 1 and 
3). That indicated the developed HPLC method had good precision and accuracy for plasma and tissue samples. Table 4 
showed the correlation coefficient of all calibration curves was more than 0.991 (plasma samples: >0.998, tissue samples: 
>0.991), and the LOD and LOQ of this method were 0.06 and 0.16 μg/mL, which ensured the reliability of the experimental 
results. The recoveries of the freeze (-20ºC)-thaw stability after three cycles, the short-time stability after 24 h stored at room 
temperature, the long-time stability after 30 days stored at -20ºC were more than 85.6% (Table 5 and 6). These results 
indicated that all biological samples were stable after three freeze-thaw cycles, short-time and long-time storage period, with 
a reduction of less than15%.  
     The present results demonstrated a reliable and reproducible HPLC method for simultaneous determination of 
tamarixetin and kaempferide in rat plasma and tissues after oral administration of TFX. Due to the high sensitivity and good 
selectivity, the HPLC results could be utilized successfully for Xiheliu on MT theory study in rats. 
 
Plasma Analysis   
 
Tamarixetin and kaempferide could be quantitative analysised using the established HPLC method, and Table 7 showed their 
concentration in plasma after oral administration. The concentration of tamarixetin and kaempferide were approximately the 
highest level within 25 min, suggesting they were absorbed very quickly. Because oral administration was the main way for 
TCM dosing and the functional compounds of TCM should be absorbed into the blood after oral administration, the result 
suggested tamarixetin and kaempferide may be the most important active constituent of Xiheliu, and even the material basis.    
 
Diuretic Activity  
 
     Diuresis was regarded as the most important effect of Xiheliu in Compendium of Materia Medica, so the diuretic 
activity would be the basic precondition for the material basis of Xiheliu. Table 8 and 9 revealed that the mixture of 
tamarixetin and kaempferide had diuretic activity after oral administration, and could accelerate the urine excretion lastingly. 
Compared with the positive control group, high dose group was collected more urine and without the disorder of ion. Further 
diuretic activity of single compound was studied, and the volume of urine excretion was not significant increased.  
 
 
 
 
 
Table 7: Concentration of tamarixetin and kaempferide in rat plasma after oral administion of TFX (n = 6) 
 
Measured concentration  (μg/mL) Compounds 
5 min 10 min 15 min 20 min 25min 30 min 40 min 60 min 120 min 180 min 240 min 
Tamarixetin 0.2 1.4 2.1 2.2 3.1 2.5 1.6 1.3 0.90 0.70 0.54 
Kaempferide 0.3 1.3 1.7 2.5 2.3 1.8 1.9 1.4 1.2 0.85 0.78 
 
 
 
 
 
 
 
 
Table 8: Urine volume of after oral administration of TFX (n = 10) 
Volume of urine (mL) Groups Dosage ( mg/kg) 
0-1 h 1-3 h 3-5 h 5-7 h 7-9 h 9-11 h 11-15 h 15-24 h 
Total 
volume 
(mL) 
pH 
Control - 3.85 6.58 6.45 5.96 5.87 5.32 9.64 15.87 59.5 7.16 
Low dose 2.3 4.01 6.83 6.51 5.84 5.96 5.66 10.35 17.12 62.3 6.84 
Medium dose 4.6 5.67* 8.12** 8.07* 7.46* 7.28 6.39 11.24 18.09 72.3** 6.76 
High dose 9.2 5.56* 8.27** 8.11** 7.38* 7.36* 6.74 10.97 18.53 72.9** 6.65 
Furosemide 2.0 11.2** 12.7** 9.18* 7.84* 6.35 4.32 7.63 10.97 70.2* 6.88 
(* p<0.05, ** p<0.01) 
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Table 9: Concentration of Na+, K+ and Cl- ions in urine samples (n = 10) 
Groups Dosage ( mg/kg) Na+ (mmol/L) K+ (mmol/L) Cl-  (mmol/L) Na+/ K+ 
Control - 88.6 40.2 86.4 1.32 
Low dose 2.3 92.1 50.1** 96.4* 1.09 
Medium dose 4.6 94.3* 48.6* 102 1.17 
High dose 9.2 97.6* 49.2** 104* 1.16 
Furosemide 2.0 99.6** 32,5* 122** 1.86* 
(* p<0.05, ** p<0.01) 
 
 
 
 
 
 
Table 10: Concentration of tamarixetin and kaempferide in tissues (n = 5) 
Compounds Liver (μg/mL) 
Heart 
(μg/mL) 
Spleen 
(μg/mL) 
Lung 
(μg/mL) 
Kidney 
(μg/mL) 
Brain 
(μg/mL) 
tamarixetin (at 10 min) 
kaempferide (at 10 min) 
0.57 
0.32 
1.15 
0.76 
0.32 
0.24 
1.04 
0.85 
0.56 
0.15 
0.28 
0.21 
tamarixetin (at 30min) 
kaempferide (at 30min)  
1.26 
0.84 
1.64 
1.08 
0.37 
0.26 
1.71 
1.07 
0.97 
0.28 
0.45 
0.14 
tamarixetin (at 60 min) 
kaempferide (at 60 min) 
0.24 
0.14 
0.77 
0.61 
0.45 
0.18 
0.73 
0.60 
0.81 
0.72 
0.62 
0.34 
 
 
 
 
 
Tissue Distribution 
 
  In MT theory, heart, liver, spleen, lung, kidney and brain were the most important target tissues of TCM. In this work, all 
those tissue samples were washed and dried twice, which effectively avoided the false positive results arising for the blood or 
content in tissues, to study the distribution of tamarixetin and kaempferide. At 30 min after oral administration of TFX to rats, 
the highest level of two analytes was observed in lung, heart and liver, and at 60 min the highest tissues were kidney, heart 
and lung. Tamarixetin and kaempferide were few even below the LOQ in all collected tissues after 90 min, there was no 
long-term accumulation after administration. Table 10 showed the concentrations of the tamarixetin and kaempferide in rat 
tissues at 10, 30 and 60 min after oral dose of TFX.  
 
Discussion 
 
  At present, the lack of material basis became the main barrier in TCM theories study (Zhang et al., 2009). The procedure of 
this research contains two steps: first, define the material basis of Xiheliu on MT theory; second, study its distribution in vivo 
and compare the result with Xiheliu on MT to assess the feasibility. An effective method for MT theory study was 
established in this work, and will serve more pertinency for the application of TCM.   
      In order to ensure the experimental results reliable, a sensitivity HPLC method was developed for quantitative 
analysis of plasma and tissues. In this method, biological sample pretreatment by solid-phase extraction resulted in an 
excellent recovery. Endogenous substance peaks were separated from the analyte peaks and acceptable selectivity was 
obtained by changing the analytic parameters. All biological samples were kept frozen for no longer than 24 h before 
pretreatment, and good stability of analytes (>86.3%) ensured the veracity of the results. The values of accuracy and 
precision were within recommended limits and the sensitivity and reproducibility were satisfactory for both analytes. The 
reliable and reproducible HPLC method made further experimental MT study possible. 
  Due to most TCM have pharmacological activity after oral administration, the material basis should be in blood after oral 
dosed. It was found that tamarixetin and kaempferide had the highest concentration in plasma by the established HPLC 
method. This result illustrated tamarixetin and kaempferide were absorbed easily after oral administration, and the material 
basis of Xiheliu on MT may be one or both of them.  
  The biological activity research carried out would be helpful to determine the material basis exactly. Diuresis was regarded 
as the most important effect of Xiheliu in Compendium of Materia Medica, so the material basis of Xiheliu must had the 
diuretic activity. The mixture of tamarixetin and kaempferide could last accelerating the urine excretion and was not caused 
the disorder of ion in rat comparing with furosemide, which demonstrated the mixture had good diuretic activity. However, 
significant diuretic activity was not proved to own by any one of them in further diuretic experiment. Therefore, tamarixetin 
and kaempferide, were regarded as the material basis of Xiheliu. 
 Tamarixetin and kaempferide were the major active constituents of Tamarix chinensis (Zhang et al., 1991). Tamarixetin had 
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been found to have antibacterial (Sultanova et al., 2001), superoxide anion scavenging (Fazilatum et al., 2005), free radical 
scavenging (Nessa et al., 2004), hepatic protective (Yannai et al., 1998) and antioxidant activity (von Moltke, et al., 2004). 
Kaempferide was reported had the peroxynitrite free radical scavenging (Calgarotto et al., 2007), antitrypanosomal and 
antileishmanial (Tasdemir et al., 2006), antioxidant and antiradical activities (Burda and Oleszek, 2001). These reports were 
consistent with the effect description of Xiheliu in Compendium of Materia Medica and Chinese Pharmacopeia. Taking into 
account the reported activities, tamarixetin and kaempferide embodied almost all effects of Xiheliu, and then they were 
designated as the material basis of Xiheliu. If tamarixetin and kaempferide were the real material basis of Xiheliu, then the 
MT theory study base on them should embody the selectivity of Xiheliu in vivo. The result of tissue distribution showed that 
the highest level of tamarixetin and kaempferide were determined in heart, lung, kidney and liver. This indicated the heart, 
lung, kidney and liver were the most important targeted tissues of tamarixetin and kaempferide. Xiheliu was recorded on 
heart, lung and kidney tropism successively in Compendium of Materia Medica, which not the same as the tissue distribution 
result exactly. Considered the liver was the most important blood-supply tissue, the tissue distribution of tamarixetin and 
kaempferide were consistent with the Xiheliu on MT and can be used to clarify the mechanism of MT theory powerfully.  
This work investigated Xiheliu on MT in rats by analyzing the material basis and its tissue distribution, and the result implied 
that tamarixetin and kaempferide were the material basis of Xiheliu on MT and the tissue distribution of material basis was 
an effective method for study the TCM on MT. In comparison with previously reported method, the significant advantages of 
this present method are that it is effective and credible. 
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